Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.58 |
| ▸ | TK1 | P04183 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015192 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL15893325 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL21423103 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL658757 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL4318242 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL15895803 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL31685506 | 0.81 | TYMS (0.48) | — | |
| SCHEMBL22916929 | 0.79 | CDA (0.44) | CDATK1TSHR | |
| SCHEMBL23240762 | 0.78 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL172249 | 0.78 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | claimed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | claimed |
| WO-2005115410-A2 | CONTEXT DEPENDENT INHIBITORS OF CYTIDINE DEAMINASES AND USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2005-12-08 | — | — | WO | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| US-20230295694-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11725205-B2 | Methods and polynucleotides for amplifying a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20100317004-A1 | PROBES | Life Technologies Corporation (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2242761-A1 | METHOD OF MYCOTOXIN DETECTION | Neoventures Biotechnology Inc. (CA) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009086621-A1 | METHOD OF MYCOTOXIN DETECTION | NEOVENTURES BIOTECHNOLOGY INC. (CA) | 2009-07-16 | — | — | WO | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| EP-1585835-B1 | Nucleic acid probes and method for detecting a target nucleic acid sequence comprising two or more cis-located nucleic acid regions | DYNAL BIOTECH LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060269916-A1 | Probes | DYNAL BIOTECH INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2005115410-A2 | CONTEXT DEPENDENT INHIBITORS OF CYTIDINE DEAMINASES AND USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1585835-A2 | NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS | Dynal Biotech Limited (GB) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004048611-A2 | NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS | DYNAL BIOTECH LIMITED (GB) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | CDA 366/4885TK1 472/4885LMNA 171/4885 |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | CDA 2/4885TK1 178/4885LMNA 2870/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | CDA 293/4885TK1 1713/4885LMNA 3119/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | CDA 275/4885TK1 950/4885LMNA 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.